Global Information
회사소개 | 문의 | 위시리스트

세계의 혈우병 시장 분석 : 종류별(혈우병 A, 혈우병 B, 혈우병 C), 시술별(온디멘드 보충요법, 정기적 보충요법), 치료법별(보충요법, 유전자 치료), 부문별 예측(2019-2026년)

Hemophilia Market Analysis by Type (Hemophilia A, Hemophilia B, Hemophilia C), by Treatment (On-demand, Prophylaxis), by Therapy (Replacement Therapy, Gene Therapy), And Segment Forecasts, 2019 - 2026

리서치사 Grand View Research, Inc.
발행일 2019년 02월 상품 코드 368045
페이지 정보 영문 119 Pages
가격
US $ 5,950 ₩ 7,128,000 Unprintable PDF by E-mail (Single User License)
US $ 6,950 ₩ 8,326,000 Printable PDF by E-mail (5-User License)
US $ 8,950 ₩ 10,722,000 Printable PDF by E-mail (Enterprise License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 혈우병 시장 분석 : 종류별(혈우병 A, 혈우병 B, 혈우병 C), 시술별(온디멘드 보충요법, 정기적 보충요법), 치료법별(보충요법, 유전자 치료), 부문별 예측(2019-2026년) Hemophilia Market Analysis by Type (Hemophilia A, Hemophilia B, Hemophilia C), by Treatment (On-demand, Prophylaxis), by Therapy (Replacement Therapy, Gene Therapy), And Segment Forecasts, 2019 - 2026
발행일 : 2019년 02월 페이지 정보 : 영문 119 Pages

세계의 혈우병 시장은 2026년까지 169억 달러 규모 시장으로 성장할 것으로 예측됩니다. 예방적 치료를 실시하기 위해 실시되는 대상 집단의 진단 필요성 고조, 정부의 혈우병 지원 프로그램 등이 시장 성장을 촉진하고 있습니다.

세계의 혈우병(Hemophilia) 시장을 조사했으며, 시장 개요, 종류·시술·치료법·지역별 시장 규모 추정과 예측, 시장 성장 촉진요인 및 저해요인 분석, 시장 점유율, 시장 기회, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 방법과 범위

  • 시장 세분화와 범위
  • 정보 조달
  • 정보 분석
  • 시장 구성과 데이터 가시화
  • 데이터 검증과 공개

제2장 주요 요약

  • 시장 전망
  • 시장 전망 : 부문별
  • 경쟁 분석

제3장 시장 변수, 동향, 범위

  • 시장 전망
  • 침투 및 성장 전망
  • 파이프라인 분석 : 임상 단계별
  • 이용자 관점 분석
  • 주요 최종사용자 : 제품별, 지역/국가별
  • 규제 체계
  • 시장 역학
  • 시장 분석 툴

제4장 세계의 혈우병 시장 분석 : 종류별

  • 정의와 범위
  • 시장 점유율 분석 : 종류별(실적치·예측치)
  • 부문 대시보드
  • 세계의 혈우병 시장 : 종류별
  • 시장 규모 추정과 예측 : 종류별
    • 혈우병 A
    • 혈우병 B
    • 혈우병 C
    • 기타

제5장 세계의 혈우병 시장 분석 : 치료법별

  • 정의와 범위
  • 시장 점유율 분석 : 치료법별(실적치·예측치)
  • 부문 대시보드
  • 세계의 혈우병 시장 : 치료법별
  • 시장 규모 추정과 예측 : 치료법별
    • 보충요법
    • 면역관용요법
    • 유전자 치료

제6장 세계의 혈우병 시장 분석 : 시술별

  • 정의와 범위
  • 시장 점유율 분석 : 시술별(실적치·예측치)
  • 부문 대시보드
  • 세계의 혈우병 시장 : 시술별
  • 시장 규모 추정과 예측 : 시술별
    • 온디멘드 보충요법(출혈시 보충요법)
    • 정기적 보충요법

제7장 세계의 혈우병 시장 분석 : 지역별

  • 정의와 범위
  • 시장 점유율 분석 : 지역별(실적치·예측치)
  • 부문 대시보드
  • 시장 현황
  • 시장 점유율과 주요 기업 : 지역별
  • SWOT 분석 : 지역별
  • 시장 규모 추정과 예측 : 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카

제8장 경쟁 분석

  • 주요 진출 기업의 최근 동향과 영향 분석
  • 기업 구분(이노베이터, 마켓 리더, 신흥 기업)
  • 벤더 상황
  • 공개회사
  • 민간기업
  • 공급업체 순위
  • 주요 기업 개요
    • Novo Nordisk
    • Biogen.
    • Chugai Pharmaceutical
    • Bayer Healthcare
    • Pfizer.
    • Shire Plc
    • Baxalta(Baxter Healthcare)
    • CSL Behring.
    • Octapharma

제9장 KOL(Key Opinion Leader)의 해설

제10장 제안

KSM 19.08.06

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • TABLE 1 Hemophilia market - Key market driver analysis
  • TABLE 2 Co-pay programs for hemophilia treatment
  • TABLE 3 Product pipeline for hemophilia drugs, 2015
  • TABLE 4 Hemophilia - Key market restraint analysis
  • TABLE 5 North America hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 6 North America hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 7 North America hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 8 U.S. hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 9 U.S. hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 10 U.S. hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 11 Canada hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 12 Canada hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 13 Canada hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 14 Europe hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 15 Europe hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 16 Europe hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 17 UK hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 18 UK hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 19 UK hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 20 Germany hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 21 Germany hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 22 Germany hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 23 France hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 24 France hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 25 France hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 26 Spain hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 27 Spain hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 28 Spain hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 29 Italy hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 30 Italy hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 31 Italy hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 32 Asia Pacific hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 33 Asia Pacific hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 34 Asia Pacific hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 35 Japan hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 36 Japan hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 37 Japan hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 38 China hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 39 China hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 40 China hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 41 India hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 42 India hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 43 India hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 44 South Korea hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 45 South Korea hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 46 South Korea hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 47 Thailand hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 58 Thailand hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 59 Thailand hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 60 Latin America hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 61 Latin America hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 62 Latin America hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 63 Brazil hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 64 Brazil hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 65 Brazil hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 66 Mexico hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 67 Mexico hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 68 Mexico hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 69 Argentina hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 70 Argentina hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 71 Argentina hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 72 Columbia hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 73 Columbia hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 74 Columbia hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 75 MEA hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 76 MEA hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 77 MEA hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 78 MEA hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 79 South Africa hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 80 South Africa hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 81 South Africa hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 82 Saudi Arabia hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 83 Saudi Arabia hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 84 Saudi Arabia hemophilia market, by therapy, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modeling for market share assessment
  • FIG. 7 Market summary (Figures in USD Million, 2015)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Hemophilia market: Market Segmentation
  • FIG. 10 Hemophilia market revenue, 2015 - 2026 (USD Million)
  • FIG. 11 Key Opportunities Prioritized
  • FIG. 12 Hemophilia Porter's analysis
  • FIG. 13 Hemophilia PESTEL analysis
  • FIG. 14 Hemophilia market type outlook key takeaways
  • FIG. 15 Hemophilia market: Type movement analysis
  • FIG. 16 Hemophilia A market, 2015 - 2026 (USD Million)
  • FIG. 17 Hemophilia B market, 2015 - 2026 (USD Million)
  • FIG. 18 Hemophilia C market, 2015 - 2026 (USD Million)
  • FIG. 19 Others market, 2015 - 2026 (USD Million)
  • FIG. 20 Hemophilia market treatment outlook key takeaways
  • FIG. 21 Hemophilia market: Treatment movement analysis
  • FIG. 22 On-demand treatment market, 2015 - 2026 (USD Million)
  • FIG. 23 Prophylaxis treatment market, 2015 - 2026 (USD Million)
  • FIG. 24 Hemophilia market therapy outlook key takeaways
  • FIG. 25 Hemophilia market: Therapy movement analysis
  • FIG. 26 Replacement therapy market, 2015 - 2026 (USD Million)
  • FIG. 27 ITI therapy market, 2015 - 2026 (USD Million)
  • FIG. 28 Gene therapy market, 2015 - 2026 (USD Million)
  • FIG. 29 Regional market place: Key takeaways
  • FIG. 30 Regional outlook, 2015 & 2026
  • FIG. 31 North America hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 32 U.S. hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 33 Canada hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 34 Europe hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 35 UK hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 36 Germany hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 37 France hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 38 Spain hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 39 Italy hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 40 Asia Pacific hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 41 Japan hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 42 China hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 43 India hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 44 South Korea hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 45 Thailand hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 46 Latin America hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 47 Brazil hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 48 Mexico hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 49 Argentina hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 50 Columbia hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 51 MEA hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 52 South Africa hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 53 Saudi Arabia hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 54 Strategy framework

The global hemophilia market is expected to reach USD 16.9 billion by 2026, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

CDC's National Center on Birth Defects and Developmental Disabilities (NCBDDD) undertakes initiatives to improving the public understanding of blood disorders and associated complications. For instance, NCBDDD supported the 'The Red Tie Challenge' initiated by the National Hemophilia Foundation (NHF) in order to spread awareness about blessing disorders such as Von Willebrand disease, hemophilia and other rare bleeding disorders. Such initiatives are anticipated to boost the market growth

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2015, including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players' growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Further key findings from the report suggest:

Hemophilia B is expected to be the fastest growing hemophilia type over the forecast period, at a CAGR of 5.8%.

The other segment, owing to spurt in the number of patients diagnosed with von Willebrand Disease (VWD), is also anticipated to witness lucrative growth over the forecast period.

On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2026.

On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.

Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Information procurement
    • 1.2.1. Purchased database
    • 1.2.2. GVR's internal database
    • 1.2.3. Secondary sources & third-party perspectives
    • 1.2.4. Primary research
  • 1.3. Information analysis
    • 1.3.1. Data analysis models
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis, by Stage
  • 3.4. User perspective analysis
    • 3.4.1. Consumer Behavior Analysis
    • 3.4.2. Market Influencer Analysis
  • 3.5. List of Key End-users, by region / by product / by country
  • 3.6. Regulatory Framework
    • 3.6.1. Reimbursement framework
    • 3.6.2. Standards & Compliances
  • 3.7. Market Dynamics
    • 3.7.1. Market Driver Analysis
    • 3.7.2. Rising neonatal population driving diagnostic rate
    • 3.7.3. Favorable government initiatives
    • 3.7.4. Rising R & D and new product development
    • 3.7.5. Rising adoption for prophylaxis treatment
    • 3.7.6. Market Restraint Analysis
    • 3.7.7. High cost of treatment
    • 3.7.8. Industry Challenges
    • 3.7.9. Low adoption rate to advanced technologies
  • 3.8. Hemophilia: Market Analysis Tools
    • 3.8.1. Industry Analysis - Porter's
      • 3.8.1.1. Supplier Power: (Low)
      • 3.8.1.2. Buyer Power: (Moderate)
      • 3.8.1.3. Substitution Threat: (Moderate)
      • 3.8.1.4. Threat from new entrant: (Moderate)
      • 3.8.1.5. Competitive rivalry: (High)
    • 3.8.2. PESTEL Analysis
      • 3.8.2.1. Political Landscape
      • 3.8.2.2. Environmental Landscape
      • 3.8.2.3. Social Landscape
      • 3.8.2.4. Technology Landscape
      • 3.8.2.5. Legal Landscape
    • 3.8.3. Major Deals & Strategic Alliances Analysis
      • 3.8.3.1. Joint Ventures
      • 3.8.3.2. Mergers & Acquisitions
      • 3.8.3.3. Licensing & Partnership
      • 3.8.3.4. Technology Collaborations
      • 3.8.3.5. Strategic Divestments
    • 3.8.4. Market Entry Strategies

Chapter 4. Hemophilia Market: Segment Analysis, By Type, 2015 - 2026 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Type market share analysis, 2018 & 2026
  • 4.3. Segment Dashboard
  • 4.4. Global Hemophilia Market, by Type, 2015 to 2026
  • 4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
    • 4.5.1. Hemophilia A
    • 4.5.2. Hemophilia B
    • 4.5.3. Hemophilia C
    • 4.5.4. Others

Chapter 5. Hemophilia Market: Segment Analysis, By Treatment, 2015 - 2026 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Type market share analysis, 2018 & 2026
  • 5.3. Segment Dashboard
  • 5.4. Global Hemophilia Market, by Treatment, 2015 to 2026
  • 5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
    • 5.5.1. Replacement therapy
    • 5.5.2. ITI therapy
    • 5.5.3. Gene therapy

Chapter 6. Hemophilia Market: Segment Analysis, By Therapy, 2015 - 2026 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Type market share analysis, 2018 & 2026
  • 6.3. Segment Dashboard
  • 6.4. Global Hemophilia Market, by Therapy, 2015 to 2026
  • 6.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
    • 6.5.1. On-demand
    • 6.5.2. Prophylaxis

Chapter 7. Hemophilia Market: Regional Market Analysis, 2015 - 2026 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Regional market share analysis, 2018 & 2026
  • 7.3. Regional Market Dashboard
  • 7.4. Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
  • 7.5. Regional Market Share and Leading Players, 2018
    • 7.5.1. North America
    • 7.5.2. Europe
    • 7.5.3. Asia Pacific
    • 7.5.4. Latin America
    • 7.5.5. Middle East & Africa
  • 7.6. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 7.6.1. North America
    • 7.6.2. Europe
    • 7.6.3. Asia Pacific
    • 7.6.4. Latin America
    • 7.6.5. Middle East & Africa
  • 7.7. Market Size, & Forecasts, and Trend Analysis, 2018 to 2025:
  • 7.8. North America
    • 7.8.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.8.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.8.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.8.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.8.5. U.S.
      • 7.8.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.8.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.8.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.8.6. Canada
      • 7.8.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.8.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.8.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.9. Europe
    • 7.9.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.9.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.9.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.9.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.5. Germany
      • 7.9.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.6. UK
      • 7.9.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.7. France
      • 7.9.7.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.7.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.7.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.8. Italy
      • 7.9.8.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.8.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.8.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.9. Spain
      • 7.9.9.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.9.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.9.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.10. Asia Pacific
    • 7.10.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
      • 7.10.1.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.1.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.1.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.2. China
      • 7.10.2.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.2.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.2.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.3. Japan
      • 7.10.3.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.3.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.3.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.4. India
      • 7.10.4.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.4.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.4.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.5. Thailand
      • 7.10.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.6. South Korea
      • 7.10.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.11. Latin America
    • 7.11.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.11.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.11.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.11.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.5. Brazil
      • 7.11.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.6. Mexico
      • 7.11.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.7. Argentina
      • 7.11.7.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.7.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.7.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.8. Columbia
      • 7.11.8.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.8.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.8.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.12. Middle East and Africa
    • 7.12.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.12.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.12.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.12.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.12.5. South Africa
      • 7.12.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.12.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.12.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.12.6. Saudi Arabia
      • 7.12.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.12.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.12.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.12.7. UAE
      • 7.12.7.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.12.7.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.12.7.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)

Chapter 8. Hemophilia Market - Competitive Analysis

  • 8.1. Recent developments & impact analysis, by key market participants
  • 8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2018
  • 8.4. Public Companies
    • 8.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 8.4.2. Company Market Share/Ranking, by region
    • 8.4.3. Competitive Dashboard Analysis
      • 8.4.3.1. Market Differentiators
      • 8.4.3.2. Synergy Analysis: Major Deals & Strategic Alliances
  • 8.5. Private Companies
    • 8.5.1. List of key emerging companies' /technology disruptors/innovators
    • 8.5.2. Funding Outlook (Optional)
    • 8.5.3. Regional network map
    • 8.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
  • 8.6. Supplier Ranking
  • 8.7. Key companies profiled
    • 8.7.1. Novo Nordisk
      • 8.7.1.1. Company Overview
      • 8.7.1.2. Financial Performance
      • 8.7.1.3. Product Benchmarking
      • 8.7.1.4. Strategic Initiatives
    • 8.7.2. Biogen.
      • 8.7.2.1. Company Overview
      • 8.7.2.2. Financial Performance
      • 8.7.2.3. Product Benchmarking
      • 8.7.2.4. Strategic Initiatives
    • 8.7.3. Chugai Pharmaceutical
      • 8.7.3.1. Company Overview
      • 8.7.3.2. Financial Performance
      • 8.7.3.3. Product Benchmarking
      • 8.7.3.4. Strategic Initiatives
    • 8.7.4. Bayer Healthcare
      • 8.7.4.1. Company Overview
      • 8.7.4.2. Financial Performance
      • 8.7.4.3. Product Benchmarking
      • 8.7.4.4. Strategic Initiatives
    • 8.7.5. Pfizer.
      • 8.7.5.1. Company Overview
      • 8.7.5.2. Financial Performance
      • 8.7.5.3. Product Benchmarking
      • 8.7.5.4. Strategic Initiatives
    • 8.7.6. Shire Plc
      • 8.7.6.1. Company Overview
      • 8.7.6.2. Financial Performance
      • 8.7.6.3. Product Benchmarking
      • 8.7.6.4. Strategic Initiatives
    • 8.7.7. Baxalta (Baxter Healthcare)
      • 8.7.7.1. Company Overview
      • 8.7.7.2. Financial Performance
      • 8.7.7.3. Product Benchmarking
      • 8.7.7.4. Strategic Initiatives
    • 8.7.8. CSL Behring.
      • 8.7.8.1. Company Overview
      • 8.7.8.2. Financial Performance
      • 8.7.8.3. Product Benchmarking
      • 8.7.8.4. Strategic Initiatives
    • 8.7.9. Octapharma.
      • 8.7.9.1. Company Overview
      • 8.7.9.2. Financial Performance
      • 8.7.9.3. Product Benchmarking
      • 8.7.9.4. Strategic Initiatives

Chapter 9. KOL Commentary

Chapter 10. Recommendations

Back to Top
전화 문의
F A Q